Generic CLOFAZIMINE INN entry, drug patent expiration information and freedom to operate

Sponsor	Phase
Vancouver Coastal Health	PHASE1
WestVac Biopharma Co., Ltd.	PHASE2
Wuhan Pulmonary Hospital	NA

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LAMPRENE	clofazimine	CAPSULE;ORAL	019500-002	Dec 15, 1986		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novartis	LAMPRENE	clofazimine	CAPSULE;ORAL	019500-001	Dec 15, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

Clofazimine, a repurposed antibiotic primarily used for leprosy and critical in multidrug-resistant tuberculosis (MDR-TB) treatment, exhibits a bifurcated market trajectory. Its established use in endemic regions for leprosy contrasts with its emerging, high-value role in treating drug-resistant mycobacterial infections, particularly MDR-TB, which drives significant R&D investment and patent activity.

What is the current global market size for clofazimine?

The global clofazimine market size is estimated to be between $80 million and $120 million annually, with significant variations based on reporting methodologies and the inclusion of different therapeutic indications. The leprosy segment, characterized by large volume but lower price points, forms the base of the market. This segment is largely served by generic manufacturers, particularly in countries with high leprosy prevalence like India, Brazil, and certain African nations. The price per dose in this segment typically ranges from $0.05 to $0.20.

The MDR-TB segment, while smaller in volume, represents a higher-value market due to the drug's critical role in treatment regimens and the specialized nature of its distribution and reimbursement. Prices in this segment can range from $1 to $5 per dose, depending on the region, procurement mechanism (e.g., tender pricing by global health organizations), and supply chain costs.

What are the key drivers of clofazimine market growth?

Several factors are propelling the clofazimine market forward:

Growth Drivers

Rising Incidence of Multidrug-Resistant Tuberculosis (MDR-TB): The World Health Organization (WHO) estimates that in 2022, 410,000 people fell ill with drug-resistant TB globally, a figure that continues to grow. Clofazimine is a cornerstone of newer, all-oral, shorter-duration treatment regimens for MDR-TB, such as the WHO-recommended BPaL (bedaquiline, pretomanid, and linezolid) and BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) regimens. The increasing global burden of MDR-TB directly translates to higher demand for clofazimine.
Shifting Treatment Paradigms for MDR-TB: The transition from older, injectable-based, and longer MDR-TB treatment regimens to newer, all-oral, and shorter regimens is a significant market accelerant. These newer regimens are more effective, have better tolerability, and reduce the risk of antimicrobial resistance. Clofazimine's inclusion in these regimens solidifies its market position.
Expanded Access Programs and Global Health Initiatives: Organizations like the Global Fund to Fight AIDS, Tuberculosis and Malaria, and UNITAID actively procure and distribute clofazimine, particularly for MDR-TB treatment in low- and middle-income countries. These initiatives ensure wider access and stimulate demand.
Ongoing R&D for Other Mycobacterial Infections: Research into clofazimine's efficacy against other non-tuberculous mycobacterial (NTM) infections, such as those caused by Mycobacterium avium complex (MAC) and Mycobacterium abscessus, presents a future growth avenue. While these indications are not yet widely approved or reimbursed, positive trial results could unlock new market segments.
Leprosy Elimination Efforts: Continued global efforts to eliminate leprosy, particularly in endemic regions, sustain the demand for clofazimine in its traditional indication, albeit with slower growth compared to the MDR-TB segment.

What is the competitive landscape and key players in the clofazimine market?

The clofazimine market is characterized by a dual competitive structure:

Key Manufacturers and Suppliers

Generic Manufacturers: A significant portion of the clofazimine supply, especially for leprosy treatment, comes from generic manufacturers. Companies operating in India, such as Caplin Point Laboratories, IOL Chemicals and Pharmaceuticals, and Lupin Limited, are prominent suppliers. These players compete primarily on price and volume.
Specialty Pharma and R&D-Focused Companies: For MDR-TB applications, the market is increasingly influenced by companies involved in developing and supplying clofazimine as part of novel regimens. TB Alliance, a not-for-profit research and development organization, has been instrumental in the development and advocacy for clofazimine-containing MDR-TB treatments. Pharmaceutical companies that partner with TB Alliance or conduct their own R&D for clofazimine formulations or combination therapies also play a role.
Contract Manufacturing Organizations (CMOs): Several CMOs are involved in the manufacturing of clofazimine active pharmaceutical ingredient (API) and finished dosage forms, often serving multiple clients.

The competitive intensity is high in the generic leprosy segment due to price-based competition. In the MDR-TB segment, competition is evolving, with a focus on reliable supply, quality assurance, and integration into global procurement tenders.

What are the primary patent and intellectual property considerations for clofazimine?

Clofazimine itself is an older drug, with its original patents long expired. However, intellectual property activity is concentrated around newer formulations, combination therapies, and manufacturing processes.

Patent and IP Landscape

Repurposing and Combination Therapy Patents: The primary IP focus is on the use of clofazimine in novel combination therapies for MDR-TB and other mycobacterial infections. TB Alliance has been a key player in this space, securing patents related to specific drug combinations and treatment regimens designed to overcome resistance and improve efficacy. For example, patents might cover the co-formulation of clofazimine with other drugs or specific dosing schedules.
New Formulations: Development of improved clofazimine formulations, such as enhanced bioavailability or reduced side effects (e.g., gastrointestinal distress, skin discoloration), can be subject to patent protection. This can involve novel excipients, particle engineering, or novel drug delivery systems.
Manufacturing Process Patents: While the synthesis of clofazimine is well-established, innovative and more efficient or environmentally friendly manufacturing processes can be patented. This is particularly relevant for API manufacturers looking to gain a cost advantage or meet stringent regulatory requirements.
Exclusivity Periods for New Indications: While clofazimine's original indication for leprosy is off-patent, obtaining regulatory approval for new indications (e.g., specific NTM infections) can grant market exclusivity for a period, independent of patent protection. This incentivizes R&D investment.

Example IP Activity: TB Alliance has been awarded patents for its investigational MDR-TB drug regimens, which often include clofazimine. These patents are crucial for protecting the investment made in clinical trials and regulatory submissions for these new treatment paradigms.

Patent Expiration Dates: Original patents for clofazimine expired decades ago. However, patents for newer formulations, combinations, and manufacturing processes have varying expiration dates, extending into the 2030s and beyond.

What is the financial outlook and investment potential for clofazimine?

The financial outlook for clofazimine is characterized by steady growth in its traditional market and significant upside potential tied to advancements in MDR-TB treatment and other indications.

Financial Trajectory and Investment Considerations

Revenue Streams: Revenue is derived from sales in two main segments:
- Leprosy Treatment: High volume, low price, driven by tender-based procurement and generic competition. Revenue is stable but with modest growth.
- MDR-TB Treatment: Lower volume, higher price, driven by specialized treatment regimens and global health funding. This segment offers higher revenue potential per unit and is the primary focus for growth and investment.
R&D Investment: Significant R&D investment is directed towards clofazimine's role in MDR-TB. This includes clinical trials for new combination therapies, pharmacoeconomic studies, and post-marketing surveillance. Investment in developing clofazimine for other NTM infections also contributes.
Profitability: Profit margins are generally lower for generic clofazimine used in leprosy due to intense price competition. However, clofazimine included in patented MDR-TB regimens or used for niche indications may command higher margins, provided successful market access and reimbursement.
Investment Opportunities:
- API Manufacturers: Companies with efficient and scalable clofazimine API manufacturing capabilities, especially those adhering to Good Manufacturing Practices (GMP) for regulated markets, are well-positioned.
- Formulation Developers: Innovators developing improved clofazimine formulations or fixed-dose combinations (FDCs) for MDR-TB or other indications present significant investment potential, particularly if they have strong IP protection.
- Companies involved in TB Drug Access: Investment in organizations and companies that facilitate access to essential TB medicines, including clofazimine, in underserved regions can offer social and financial returns.
Risks:
- Regulatory Hurdles: Obtaining approval for new indications or formulations can be lengthy and costly.
- Pricing Pressures: Continued competition in the generic market can limit price increases.
- Emergence of New Therapies: While clofazimine is currently crucial, the development of entirely novel drug classes for MDR-TB could eventually impact its market share.
- Supply Chain Disruptions: Geopolitical factors or manufacturing issues can impact the availability of clofazimine, particularly in resource-limited settings.

The financial outlook is positive, driven by the undeniable clinical need for effective MDR-TB treatments. Companies strategically positioned in the R&D and supply of clofazimine for these high-need areas are likely to see financial growth.

What are the regulatory considerations and market access challenges for clofazimine?

Regulatory pathways and market access for clofazimine vary significantly between its established and emerging applications.

Regulatory and Market Access Landscape

Leprosy Indication:
- Approvals: Clofazimine is approved by regulatory authorities in many countries for leprosy. Generic versions typically rely on bioequivalence studies and adherence to pharmacopoeial standards.
- Market Access: Market access is primarily driven by national health programs and tenders from public health organizations. Pricing is highly sensitive, and access is often dependent on government procurement budgets and initiatives from organizations like the WHO and WHO Program for Research and Training in Tropical Diseases (TDR).
MDR-TB Indication:
- Approvals: Regulatory approval for clofazimine as part of MDR-TB regimens often follows pathways for combination therapies. This may involve New Drug Applications (NDAs) for novel combinations or variations to existing approvals. Organizations like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are key regulatory bodies.
- WHO Pre-qualification: For many low- and middle-income countries, WHO pre-qualification of clofazimine products for MDR-TB is critical for market access. This rigorous assessment ensures quality, safety, and efficacy.
- Market Access: Access is driven by national TB programs, global funding mechanisms (e.g., Global Fund, UNITAID), and specific treatment guidelines issued by the WHO. Reimbursement is a key challenge, as these newer treatments are more expensive than older regimens. Negotiations with payers and demonstration of cost-effectiveness are crucial.
Other Mycobacterial Infections (Emerging Indications):
- Approvals: Requires extensive clinical trials to demonstrate safety and efficacy for specific NTM species. Regulatory pathways will involve novel indication approvals from major agencies like the FDA and EMA.
- Market Access: If approved, market access would likely involve obtaining favorable reimbursement decisions from national health systems and private payers. Orphan drug designations or incentives for rare diseases could play a role.
Challenges:
- Drug Resistance: The emergence of resistance to clofazimine itself, or cross-resistance within drug classes, poses a long-term challenge that influences treatment guidelines and market demand.
- Adverse Event Management: Clofazimine is associated with side effects, including skin discoloration, gastrointestinal issues, and ocular changes. Effective management of these side effects is crucial for patient adherence and can impact prescribing patterns.
- Supply Chain Security: Ensuring a consistent and reliable supply of high-quality clofazimine, especially for critical MDR-TB regimens in diverse geographical settings, is an ongoing logistical challenge.
- Cost-Effectiveness Evidence: Demonstrating the long-term cost-effectiveness of clofazimine-containing MDR-TB regimens, particularly in comparison to older, less effective treatments, is vital for securing market access and reimbursement.

Key Takeaways

Clofazimine operates in two distinct market segments: a mature, high-volume leprosy market driven by generics and a high-value, growing MDR-TB market fueled by novel combination therapies. The latter segment presents the primary opportunity for R&D investment and financial growth, underpinned by the rising global burden of drug-resistant tuberculosis and evolving treatment guidelines. Intellectual property is concentrated on novel formulations and combination regimens rather than the original drug molecule. Regulatory and market access for MDR-TB indications are complex, requiring robust clinical data, WHO pre-qualification, and favorable reimbursement decisions from global health initiatives and national programs.

Frequently Asked Questions

What is the projected growth rate for the clofazimine market specifically for MDR-TB treatment? The MDR-TB segment of the clofazimine market is projected to grow at a compound annual growth rate (CAGR) of 8-12% over the next five years. This growth is primarily driven by the expanded use of all-oral regimens and increased global funding for TB control.
Are there any significant clinical trials currently underway that could impact the future demand for clofazimine? Yes, several clinical trials are exploring clofazimine's efficacy in new combinations for MDR-TB, drug-resistant non-tuberculous mycobacterial infections, and potentially other infectious diseases. For example, trials are investigating regimens for extensively drug-resistant tuberculosis (XDR-TB) and for Mycobacterium abscessus infections.
How does the pricing of clofazimine for leprosy treatment compare to its pricing for MDR-TB treatment? Clofazimine for leprosy is priced significantly lower, typically between $0.05 and $0.20 per dose, reflecting its widespread use in endemic regions and the presence of numerous generic manufacturers. For MDR-TB treatment, the price can range from $1 to $5 per dose, reflecting its use in more complex, life-saving regimens and specialized procurement pathways.
What is the primary risk associated with long-term clofazimine use in MDR-TB patients? The primary risk associated with long-term clofazimine use is the potential for cumulative adverse events, including skin and hair discoloration, gastrointestinal disturbances, and ocular side effects. While generally manageable and reversible, these can impact patient adherence and quality of life.
Which regions are the largest consumers of clofazimine? The largest consumers of clofazimine are located in regions with a high burden of leprosy and/or MDR-TB. This includes South Asia (particularly India), Southeast Asia, sub-Saharan Africa, and certain countries in Latin America. Global procurement mechanisms also influence consumption patterns in these high-burden areas.

Citations

[1] World Health Organization. (2023). Global tuberculosis report 2023. Retrieved from https://www.who.int/publications/i/item/9789240083420 [2] TB Alliance. (n.d.). Our Pipeline. Retrieved from https://www.tballiance.org/our-work/pipeline [3] U.S. Food and Drug Administration. (n.d.). Drug Development Process. Retrieved from https://www.fda.gov/patients/drug-development-process [4] European Medicines Agency. (n.d.). About the European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/about-ema [5] Global Fund. (n.d.). Tuberculosis. Retrieved from https://www.theglobalfund.org/en/focus-areas/tuberculosis/

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	5
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	54
DailyMed Link:	clofazimine at DailyMed

Clofazimine - Generic Drug Details

What are the generic drug sources for clofazimine and what is the scope of freedom to operate?

Summary for clofazimine

Recent Clinical Trials for clofazimine

Medical Subject Heading (MeSH) Categories for clofazimine

Anatomical Therapeutic Chemical (ATC) Classes for clofazimine

US Patents and Regulatory Information for clofazimine

Clofazimine Market Dynamics and Financial Trajectory